Wellington Shields Capital Management LLC decreased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 5.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 39,500 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the quarter. Wellington Shields Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $2,421,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Bristol-Myers Squibb by 0.3% in the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after acquiring an additional 333,685 shares during the period. BlackRock Inc. lifted its holdings in Bristol-Myers Squibb by 2.4% in the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after acquiring an additional 2,367,864 shares during the period. Dodge & Cox lifted its holdings in Bristol-Myers Squibb by 1.6% in the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after acquiring an additional 459,271 shares during the period. Jennison Associates LLC lifted its holdings in Bristol-Myers Squibb by 16.2% in the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after acquiring an additional 3,735,453 shares during the period. Finally, Northern Trust Corp lifted its holdings in Bristol-Myers Squibb by 3.9% in the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after acquiring an additional 910,496 shares during the period. 71.55% of the stock is owned by hedge funds and other institutional investors.
Shares of Bristol-Myers Squibb Co (BMY) opened at $67.45 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. Bristol-Myers Squibb Co has a 12-month low of $51.56 and a 12-month high of $70.05. The company has a market capitalization of $110,885.03, a P/E ratio of 114.32, a P/E/G ratio of 2.08 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the previous year, the business earned $0.63 earnings per share. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. analysts predict that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.37%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is 271.19%.
In other news, Director Theodore R. Samuels II purchased 4,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the transaction, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.23% of the stock is currently owned by insiders.
BMY has been the subject of a number of analyst reports. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Tuesday, December 5th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Monday, December 11th. Vetr cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective for the company. in a research report on Friday, December 22nd. Zacks Investment Research cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Credit Suisse Group set a $62.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $66.30.
WARNING: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/13/wellington-shields-capital-management-llc-decreases-position-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.